GW501516 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-04-15. Where a claim depends on a specific study, the study is described rather than over-claimed.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
GW501516 acts as a selective agonist at PPARδ, a nuclear receptor that regulates transcription of genes involved in lipid handling and energy metabolism. Activation of PPARδ in preclinical models increases fatty acid oxidation, mitochondrial biogenesis, and exercise endurance in rodents. These effects have made the compound a subject of metabolic research and also a target for sport anti-doping rules. In humans, however, controlled studies are limited, and whether similar endurance or metabolic changes occur at tolerated exposures remains an open question. The receptor’s broad tissue distribution also means downstream effects may vary by organ and condition.
Detection of GW501516 in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. Urine is a common matrix in anti-doping analysis, while blood or plasma may be used in research settings. Sample preparation can involve enzymatic hydrolysis, protein precipitation, or solid-phase extraction before instrumental analysis. Because the compound undergoes metabolism, assays may target the parent molecule, one or more metabolites, or both. Detection windows are not fixed; they depend on factors such as dose, route, individual metabolism, and assay sensitivity. Reference standards are required for accurate identification and quantification.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 317318-70-0 | Unique identifier for the compound. |
| Chemical class | PPARδ agonist | Synthetic ligand for peroxisome proliferator-activated receptor delta. |
| Appearance | White to off-white solid | Typical form of research-grade material. |
| Solubility | Soluble in DMSO and ethanol | Poorly soluble in water. |
| Typical storage | -20°C | Recommended for long-term storage of stock solutions. |
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.
Beginning in 1986, members of the University Health Center including Presbyterian University Hospital, Falk Clinic, the Pittsburgh Cancer Institute and Eye & Ear Hospital consolidated into the Medical and Health Care Division (MHCD) and led by Detre, became closely linked administratively, although Presbyterian University Hospital remained separate. In 1990, MHCD acquired neighboring Montefiore Hospital which merged with Presbyterian University Hospital to form the "University of Pittsburgh Medical Center" (shortened to UPMC), the first time that name was officially used. UPMC then formed a network of specialty and community hospitals in 1994 named the Tri-State Health System and established a for-profit health insurance division, UPMC Health Plan, which contracted with these hospitals. In 1996, UPMC acquired South Side, Aliquippa and Braddock hospitals. Meanwhile, UPMC began to merge with several of the already affiliated Tri-State hospitals including St. Margaret Memorial, Shadyside, and Passavant hospitals in 1997 and Magee-Womens Hospital in 1998. The acquisition and mergers consolidated the Tri-State Health System into a significant portion of the UPMC health system. Due to the immense growth of the medical center, as well as the university's concerns over financial risks associated with faculty practice in the face of national changes in health care reimbursement, the University of Pittsburgh and UPMC separated in 1998, launching UPMC as an independent nonprofit corporation supporting the university.
==== Marketed ==== Dextromethorphan (DXM; Robitussin) Dextropropoxyphene (Darvon) Dimenhydrinate (Dramamine) Diphenhydramine (Benadryl) Mepyramine (pyrilamine) (Anthisan) Mifepristone (Korlym, Mifeprex)
By 2015, SF Holding's revenue reached RMB 47.3 billion, up 23.6% year-on-year, and its profit was RMB 1.967 billion, up 80% year-on-year. Its core profit after deducting non-recurring business was RMB 1.623 billion, up 76% year-on-year. Its gross profit margin increased from 17.55% to 20.42%. Its air fleet increased to over 30 all-cargo charter flights, with over 30,000 business locations, over 200 hubs, and more than 15,000 operating vehicles. On May 23, 2016, SF Express applied for a backdoor listing on the Shenzhen A-share market. Maanshan Dingtai Rare Earth & New Material Co., Ltd. announced that it would acquire 100% of SF Holding for RMB 44.3 billion, of which Maanshan Dingtai Rare Earth & New Material Co., Ltd. would pay SF Holding shareholders by issuing 3.95 billion new shares at RMB 10.76 per share. After the transaction is completed, Mingde Holding, controlled by Wang Wei, the founder and CEO of SF Express, would hold 64.58% of the shares of the new company. The company was listed on the Shenzhen Stock Exchange in January 2017. In February of the same year, Maanshan Dingtai Rare Earth & New Material Co., Ltd. was officially renamed SF Holding Co., Limited. On February 9, 2018, SF Holding invested RMB 45.9 billion to participate in the investment and construction of Ezhou Airport. In July 2018, SF Holding completed the acquisition of a 75% stake in HAVI China Holding LLC, planning to expand its cold chain logistics business in Mainland China, Hong Kong and Macau. In the same year, it completed the acquisition of Guangdong Xinbang Logistics Co., Ltd.
Sources: en.wikipedia.org
The mass-to-charge ratio (m/Q) is a physical quantity relating the mass (quantity of matter) and the electric charge of a given particle, expressed in units of kilograms per coulomb (kg/C). It is most widely used in the electrodynamics of charged particles, e.g. in electron optics and ion optics. It appears in the scientific fields of electron microscopy, cathode ray tubes, accelerator physics, nuclear physics, Auger electron spectroscopy, cosmology and mass spectrometry. The importance of the mass-to-charge ratio, according to classical electrodynamics, is that two particles with the same mass-to-charge ratio move in the same path in a vacuum, when subjected to the same electric and magnetic fields. Some disciplines use the charge-to-mass ratio (Q/m) instead, which is the multiplicative inverse of the mass-to-charge ratio. The CODATA recommended value for an electron is Q/m = −1.75882000838(55)×1011 C⋅kg−1.
2,5-DMA has been encountered as a novel designer drug, with capsules of 200 mg of the hydrobromide salt, equivalent to 170 mg of the hydrochloride salt. It was initially misrepresented as mescaline or MDA before being named DMA. According to Shulgin, this might be an effective dose level that has not been formally clinically explored.
The Grainyhead-like (Grhl) gene family is a group of highly conserved transcription factors, which work to regulate the expression of specific target genes. Grainyhead (Grh) was originally identified in Drosophila as being implicated within development through its role of regulating numerous genetic pathways. While Drosophila has only one Grh gene, there are three homologues currently known across other species (Grhl1-3). It appears that all members of the Grhl gene family are involved in epidermal barrier integrity, including its formation and repair, and are tightly regulated to prevent physical defects. The Grhl family of genes are found in a range of organisms, from humans to fish and fungi, and all have similar roles to each other in regards to the developmental processes that they have a role in regulating. This could indicate that the Grhl genes could be one of the earliest genes to arise within our genome, providing vital functions for survival of an early common ancestor.
Sources: en.wikipedia.org
Cardarine is a common name for GW501516, a synthetic PPARδ agonist developed for research. It has not been approved as a medication in any country. It is classified as an unapproved drug and a prohibited substance in sport.
No. Cardarine is not an anabolic steroid; it belongs to a different chemical class that targets PPARδ. Steroids act primarily through androgen receptors, while cardarine acts through a nuclear receptor involved in metabolism.
Some rodent studies reported increased endurance and changes in fat metabolism after cardarine exposure. Long-term studies in animals also raised concerns about cancer in certain tissues. Human trial data are limited, so these findings cannot be directly translated to people.
Cardarine targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not bind the androgen receptor in the way SARMs do.